302 related articles for article (PubMed ID: 33224141)
1.
Kacew A; Sweis RF
Front Immunol; 2020; 11():575258. PubMed ID: 33224141
[No Abstract] [Full Text] [Related]
2. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Chen S; Zhang N; Wang T; Zhang E; Wang X; Zheng J
Front Immunol; 2020; 11():1900. PubMed ID: 32983112
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptor (
Al-Obaidy KI; Cheng L
J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
[TBL] [Abstract][Full Text] [Related]
6. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Pouessel D; Neuzillet Y; Mertens LS; van der Heijden MS; de Jong J; Sanders J; Peters D; Leroy K; Manceau A; Maille P; Soyeux P; Moktefi A; Semprez F; Vordos D; de la Taille A; Hurst CD; Tomlinson DC; Harnden P; Bostrom PJ; Mirtti T; Horenblas S; Loriot Y; Houédé N; Chevreau C; Beuzeboc P; Shariat SF; Sagalowsky AI; Ashfaq R; Burger M; Jewett MA; Zlotta AR; Broeks A; Bapat B; Knowles MA; Lotan Y; van der Kwast TH; Culine S; Allory Y; van Rhijn BW
Ann Oncol; 2016 Jul; 27(7):1311-6. PubMed ID: 27091807
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.
Foth M; Ismail NFB; Kung JSC; Tomlinson D; Knowles MA; Eriksson P; Sjödahl G; Salmond JM; Sansom OJ; Iwata T
J Pathol; 2018 Nov; 246(3):331-343. PubMed ID: 30043421
[TBL] [Abstract][Full Text] [Related]
8. Precision and predictive medicine in urothelial cancer: are we making progress?
Bellmunt J; Orsola A; Sonpavde G
Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
[TBL] [Abstract][Full Text] [Related]
9. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
[TBL] [Abstract][Full Text] [Related]
10. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
Zhou C; Lin A; Cao M; Ding W; Mou W; Guo N; Chen Z; Zhang J; Luo P
Front Immunol; 2021; 12():634741. PubMed ID: 34220801
[TBL] [Abstract][Full Text] [Related]
11. Distinct microRNA alterations characterize high- and low-grade bladder cancer.
Catto JW; Miah S; Owen HC; Bryant H; Myers K; Dudziec E; Larré S; Milo M; Rehman I; Rosario DJ; Di Martino E; Knowles MA; Meuth M; Harris AL; Hamdy FC
Cancer Res; 2009 Nov; 69(21):8472-81. PubMed ID: 19843843
[TBL] [Abstract][Full Text] [Related]
12. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
[TBL] [Abstract][Full Text] [Related]
13. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
di Martino E; Alder O; Hurst CD; Knowles MA
Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
16. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
Masson-Lecomte A; Vordos D; de la Taille A; Neuzillet Y; Radvanyi F; Allory Y
Prog Urol; 2013 Feb; 23(2):96-8. PubMed ID: 23352301
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin.
Hafner C; Hartmann A; Vogt T
J Invest Dermatol; 2007 Jul; 127(7):1572-3. PubMed ID: 17568799
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
[TBL] [Abstract][Full Text] [Related]
19. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
20. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
